Spinal Motor Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Spinal motor neurons are large, multipolar neurons that form the final common pathway for motor control. They directly innervate skeletal muscles and are the primary efferent output of the motor system. These neurons exhibit selective vulnerability in amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). [1]
| Property | Value | [2]
|----------|-------| [3]
| Cell Type Name | Spinal Motor Neurons | [4]
| Allen Atlas ID | Spinal cord, ventral horn, alpha motor neurons | [5]
| Lineage | Neural progenitor > Motor neuron > Spinal motor neuron | [6]
| Marker Genes | MN1, ISL1, LHX3, CHAT, SLC18A2 (VMAT2), SLC5A7 (CHT1) | [7]
| Brain Regions | Spinal cord ventral horn (lamina IX) |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000100 | motor neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000100 | motor neuron | Exact |
| Cell Ontology | CL:2000047 | brainstem motor neuron | Exact |
Spinal motor neurons are among the largest neurons in the human body, with cell bodies 30-70 μm in diameter:
Each spinal motor neuron innervates 150-200 muscle fibers (in humans), forming a motor unit:
Motor neurons integrate multiple inputs:
| Property | Type S | Type FR | Type FF |
|---|---|---|---|
| Axon conduction | Slow | Medium | Fast |
| Muscle fiber type | Slow oxidative | Fast oxidative | Fast glycolytic |
| Force | Low | Medium | High |
| Fatigability | Fatigue-resistant | Fatigue-resistant | Fatigable |
| Size | Small | Medium | Large |
Spinal motor neurons are the primary target in ALS:
Single-nucleus RNA sequencing reveals molecular signatures:
| Drug | Target | Status |
|---|---|---|
| Riluzole | Glutamate excitotoxicity | Approved (modest benefit) |
| Edaravone | Oxidative stress | Approved for ALS |
| AMX0035 | SOD1 aggregation, ER stress | Phase 3 |
| Tofersen | SOD1 gene silencing | FDA approved (2023) |
| BIIB105 | ATXN2 ASO | Phase 1/2 |
The study of Spinal Motor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011. ↩︎
Cook C, Petrucelli L. A critical evaluation of the role of optineurin in amyotrophic lateral sclerosis. Front Cell Neurosci. 2022. ↩︎
Al-Chalabi A, Hardiman O, Kiernan MC, et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016. ↩︎
Burg T, Groba S, Marteil G, et al. Motor neuron disease: mechanisms and emerging therapeutics. Nat Rev Neurol. 2023. ↩︎
Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014. ↩︎
Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006. ↩︎
Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009. ↩︎
Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016. ↩︎